IL6 and depressive symptom measurement: This is further supported by the observation that intracranial infusion of proinflammatory cytokine IL-6 increases depression-associated behavior [8], and systemic treatment with monoclonal IL-6 antibody can effectively reduce circulating IL-6 and promote resilience to chronic social stress-induced depression-like behaviors [9].